Clinical trial
Evolution Of Growth Rate In Children With Growth Retardation Due to…
NCT00163189 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00163189 |
|---|---|
| Title | Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm |
| Official title | Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | Somatropin |
| Enrollment | 98 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Sep 13, 2005 |
| Last update posted | Feb 21, 2024 |
| Countries | France |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: